News

July, 8th 2010
ANTAGENE is announcing the marketing of the PLL-A test in tibetan Terrier, Fox Terrier (Wire), German hunting Terrier, Jack Russel Terrier and Miniature Bull Terrier.
To order PLL-A test, click here
_____________________________________________________________________________________

May, 18th 2010
ANTAGENE is announcing the marketing of the HSF4-A test in Australian Shepherd.
To order HSF4-A test, click here.

______________________________________________________________________________________
December, 22nd 2009
During the Christmas break, ANTAGENE is open and will assure the follow-up of your files.
Exceptionally ANTAGENE will close the Saint Sylvester Day (Thursday 31st December)

All team ANTAGENE wishes you a merry Christmas and a very beautiful year 2010.

______________________________________________________________________________________

November, 19th 2008
ANTAGENE is announcing a partnership with OptiGen for the NC-A test in AmStaff

ANTAGENE is pleased to partner with OptiGen in the USA to assist North American owners of American Staffordshire Terriers
who whish to test their dog's DNA...

Read the next...

8th September 2008 ANTAGENE is announcing the marketing of the NCL-A test in AmStaff The Cerebellar Ataxia is a neurological disease causing a nervous system disorder. In the American Staffordshire Terrier, the disease generally breaks out between 3 and 5 years... Read the next... Lyon, France, February 1, 2007 Lyon, France, March 2008 The prcd-PRA test : Europeen patent is validated. Prcd-PRA test is protected by an international patent from Cornell Research Foundation. OptiGen holds an international exclusive license for this test. This licence has been recently validated in Europe, it confirmes Optigen rights on commercialization of this genetic test. Two companies in Europe are approved to act as OptiGen’s agents by receiving blood samples, extracting DNA, and shipping the DNA to OptiGen for testing in the OptiGen labs. These companies are : VHL in The Netherlands Antagene in France No other company serves as agent for sample shipments in Europe This partnership is officially shown on Optigen website (www.optigen.com) Instructions OPTIGEN's TESTS (PRA-prcd or CEA) Lyon, France, February 1, 2007 ANTAGENE announces commercialization of a new DNA test for the diagnosis of Familial Nephropathy in English Cocker Spaniel ANTAGENE, a biotechnology company specialized in canine and feline genomics, announced it obtained an exclusive european license for the genetic test for the Familial Nephropathy (FN) in dog. This inherited kidney disease is also referred to as Alport's syndrome in humans. The Familial Nephropathy is a juvenile-onset fatal kidney disease. Dogs typically develop chronic renal failure from 6 months of age, often leading to death before 2 years of age. Current genetic data on european English Cocker Spaniel population indicates a frequency of at least 20 % of dogs carrying the genetic anomaly responsible for this autosomal recessive genetic disease. This new genetic test allows precocious diagnosis of this disease, before manifestation of the first clinical signs. Thanks to this test, breeders will be able to detect very early carrier puppies, to select breeding animals and to adapt breeding strategies in order to avoid producing and selling puppies affected by Familial Nephropathy. Gene and mutation causing Familial Nephropathy in the English Cocker Spaniel have been discovered by the team of Pr Keith Murphy from Texas A&MUniversity. ANTAGENE has an exclusive license for Europe from MERLOGEN LLC (USA) for Familial Nephropathy testing in dog.